These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12547606)

  • 1. Effect of priming on subsequent response to inactivated influenza vaccine.
    Potter CW; Jennings R
    Vaccine; 2003 Feb; 21(9-10):940-5. PubMed ID: 12547606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine.
    Coulter A; Harris R; Davis R; Drane D; Cox J; Ryan D; Sutton P; Rockman S; Pearse M
    Vaccine; 2003 Feb; 21(9-10):946-9. PubMed ID: 12547607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal immunisation with influenza-ISCOM induces strong mucosal as well as systemic antibody and cytotoxic T-lymphocyte responses.
    Sjölander S; Drane D; Davis R; Beezum L; Pearse M; Cox J
    Vaccine; 2001 Jul; 19(28-29):4072-80. PubMed ID: 11427284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice.
    Ben Ahmeida ET; Gregoriadis G; Potter CW; Jennings R
    Vaccine; 1993 Oct; 11(13):1302-9. PubMed ID: 8296483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines.
    Ghendon Y; Markushin S; Krivtsov G; Akopova I
    Arch Virol; 2008; 153(5):831-7. PubMed ID: 18297235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza virus subtype cross-reactivities of haemagglutination inhibiting and virus neutralising serum antibodies induced by infection or vaccination with an ISCOM-based vaccine.
    Rimmelzwaan GF; Baars M; van Beek R; de Lijster P; de Jong JC; Claas EC; Osterhaus AD
    Vaccine; 1999 Jun; 17(20-21):2512-6. PubMed ID: 10418897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.
    Eliasson DG; Helgeby A; Schön K; Nygren C; El-Bakkouri K; Fiers W; Saelens X; Lövgren KB; Nyström I; Lycke NY
    Vaccine; 2011 May; 29(23):3951-61. PubMed ID: 21481325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine.
    Katz JM; Lu X; Young SA; Galphin JC
    J Infect Dis; 1997 Feb; 175(2):352-63. PubMed ID: 9203656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunopotentiation of humoral and cellular responses to inactivated influenza vaccines by two different adjuvants with potential for human use.
    Deliyannis G; Jackson DC; Dyer W; Bates J; Coulter A; Harling-McNabb L; Brown LE
    Vaccine; 1998 Dec; 16(20):2058-68. PubMed ID: 9796065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of mice against an influenza virus infection by oral vaccination with viral nucleoprotein incorporated into immunostimulating complexes.
    Scheepers K; Becht H
    Med Microbiol Immunol; 1994 Nov; 183(5):265-78. PubMed ID: 7715538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses.
    Hu KF; Elvander M; Merza M; Akerblom L; Brandenburg A; Morein B
    Clin Exp Immunol; 1998 Aug; 113(2):235-43. PubMed ID: 9717973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune response of mice to immunization with subunit influenza A vaccine in DTP vaccine.
    Potter CW; Tamizifar H; Jennings R
    Vaccine; 1995 Feb; 13(3):253-60. PubMed ID: 7631510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chitosan as an adjuvant for parenteral inactivated influenza vaccines].
    Gendon IuZ; Markushin SG; Krivtsov GG; Akopova II
    Vopr Virusol; 2008; 53(5):14-9. PubMed ID: 19069787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
    Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunostimulating complexes (ISCOMs) for nasal vaccination.
    Hu KF; Lövgren-Bengtsson K; Morein B
    Adv Drug Deliv Rev; 2001 Sep; 51(1-3):149-59. PubMed ID: 11516786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain.
    de Wit E; Munster VJ; Spronken MI; Bestebroer TM; Baas C; Beyer WE; Rimmelzwaan GF; Osterhaus AD; Fouchier RA
    J Virol; 2005 Oct; 79(19):12401-7. PubMed ID: 16160167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics, localization and isotype profile of antibody responses to immune stimulating complexes (iscoms) containing human influenza virus envelope glycoproteins.
    Sjölander A; Lövgren Bengtsson K; Johansson M; Morein B
    Scand J Immunol; 1996 Feb; 43(2):164-72. PubMed ID: 8633196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection.
    Bungener L; Geeraedts F; Ter Veer W; Medema J; Wilschut J; Huckriede A
    Vaccine; 2008 May; 26(19):2350-9. PubMed ID: 18400340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.